Industry News

Eli Lilly and Co. through a painful period of job cuts and patent expirations while steering toward new products, will retire at the end of the year. Lechleiter will step down as president and CEO of the Indianapolis pharmaceutical giant on Dec. 31. David Ricks, a senior vice president and president of Lilly Bio-Medicines, will take over Jan. 1.."/>
Eli Lilly CEO John Lechleiter to retire [The Indianapolis Star]
Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider with a select therapeutic development pipeline, announces today that as of 5:00 p.m., Eastern Time, on July 27, 2016 it will effect a 1- for-10 reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on Thursday, July 28, 2016. At the Annual Meeting of..."/>
Caladrius Biosciences Announces 1-for-10 Reverse Split
Advanzeon Solutions, Inc. announced today that its Chairman and CEO, Clark A. Marcus, has rejoined the America’ s Agenda: Health Care For All Board of Directors, effective immediately. America’ s Agenda, a non-profit organization, brings together national and international labor unions, businesses, health care providers, and government leaders who share a common commitment of providing access to affordable, high quality health care for every American."/>
Advanzeon Solutions, Inc. CEO Clark A. Marcus Returns to the Board of America’s Agenda: Health Care for All
INC Research Holdings, Inc., a leading, global Phase I to IV contract research organization, today announced the launch of the Company’ s Vaccine Catalyst Site network as part of its Catalyst program introduced earlier this year to strengthen collaborations with clinical research sites worldwide, ultimately enhancing patient focus and optimizing study delivery to drive improved predictability and increased efficiency for customers."/>
INC Research Extends Catalyst Program with Launch of Vaccine Catalyst Site Network
Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the subscription period for its previously announced rights Offering of units at a subscription price of $4.10 per unit expired on July 26, 2016, and these rights are no longer exercisable.. The results of the oversubscribed Offering and Onconova’ s estimates regarding the..."/>
Onconova Announces Expiration of Oversubscribed Rights Offering
Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider with a select therapeutic development pipeline, announces today that as of 5:00 p.m., Eastern Time, on July 27, 2016 it will effect a 1- for-10 reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on Thursday, July 28, 2016."/>
Caladrius Biosciences Announces 1-for-10 Reverse Split
Vermillion company, today announced an agreement with Independent Medical Systems, a preferred provider organization based in Dallas, Texas for coverage of ASPiRA LABS' ovarian cancer risk assessment test, OVA1. "We are pleased to announce OVA1 expansion in our home state with a leading PPO network provider," said Valerie Palmieri, President and CEO of Vermillion, Inc. "Our technology helps define appropriate physician..."/>
ASPiRA LABS Expands Coverage for OVA1 in Texas
EndoChoice Holdings, Inc. announced today that it will release its second quarter 2016 financial results on Wednesday, August 3, 2016 after the market closes. EndoChoice will hold a conference call on Wednesday, August 3, 2016 at 4:30 p.m. ET to discuss the results. The dial-in numbers are 328-5344 for domestic callers and 317-5469 for international callers."/>
EndoChoice to Report Second Quarter 2016 Financial Results on August 3, 2016
Bavarian Nordic A/S today announced the initiation of a Phase 1 clinical trial of MVA-BN YF, a new vaccine candidate based on the Company's proprietary MVA-BN platform, designed to protect against yellow fever virus. The study is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. "We are very pleased to see the advancement of this novel vaccine into human studies."/>
Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine
GeoVax Labs, Inc., a biotechnology company developing human vaccines, today provided an update on its Tetravalent Hemorrhagic Fever Vaccine program, including a demonstration that its vaccines produce non-infectious virus-like particles for each of the four virus targets-- Ebola-Zaire, Ebola-Sudan, Marburg, and Lassa. GeoVax's vaccine is based on the Company's novel Modified Vaccinia Ankara VLP platform, which generates noninfectious VLPs."/>
GeoVax Reports Progress With Hemorrhagic Fever Vaccine Program
Boston Scientific Corporation today announced that it has acquired Cosman Medical, Inc., a privately held Burlington, Mass. manufacturer of radiofrequency ablation systems. The Cosman Medical team and products will become part of the Boston Scientific Neuromodulation business, which offers a range of Spinal Cord Stimulator systems to treat patients with chronic pain, and Deep Brain Stimulation systems* for the treatment of..."/>
Boston Scientific Announces Acquisition of Cosman Medical
McKesson Corporation today announced preliminary voting results from its Annual Meeting of Stockholders, held earlier today in Richmond, Virginia. All Board members were reelected, the advisory vote on executive compensation was approved and all Board vote recommendations were supported."/>
McKesson Announces Preliminary Voting Results from 2016 Annual Meeting of Stockholders
BioTime, Inc., a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will release second quarter financial and operating results on Tuesday, August 9, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Tuesday, August 9, 2016 at 4:30 p.m. Eastern/ 1:30 p.m. Pacific to discuss the results and recent corporate developments."/>
BioTime, Inc. to Report Second Quarter Results on August 9, 2016
Pfenex Inc. announced today that its second quarter 2016 financial results will be released on Monday, August 8, 2016, before market open. At 8:30 am Eastern Time, Pfenex management will host a conference call to discuss the financial results and provide a business update. A press release outlining the financial results and business update will be publicly distributed prior to the call."/>
Pfenex To Report Second Quarter 2016 Results and Provide Business Update on Monday, August 8, 2016
PositiveID Corporation, a life sciences company focused on detection and diagnostics, announced today that it will exhibit its FDA-cleared Caregiver ® non-contact thermometer at the Association for Healthcare Resource and Materials Management Conference from July 31- August 3, 2016, at the San Diego Convention Center in San Diego, CA.. Caregiver is a clinical grade, infrared thermometer for measurement of forehead temperature in adults,..."/>
PositiveID to Exhibit its Caregiver Non-Contact Thermometer at the Association for Healthcare Resource and Materials Management Conference July 31-August 3
Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 36 th Annual Growth Conference on Wednesday, August 10, 2016 at 8:00 AM EDT at the InterContinental Boston, Boston MA.. This presentation will be webcast live and may be accessed by visiting the Investor..."/>
Histogenics Corporation to Present at the Canaccord Genuity Growth Conference
Catasys, Inc., a provider of proprietary data, predictive analytics, and modeling based behavioral health management services for health plans, announced today that it has extended its On Trak™- H solution in Florida to Medicare Advantage members with one of the nation's leading health plans. With the addition of Medicare members to this plan's existing program means their eligible commercial and Medicare Advantage members will be covered..."/>
Catasys Expands Rollout of OnTrak-H Solution in Florida with Leading National Health Insurance Provider
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has completed patient enrollment in the Phase 3 study of aceneuramic acid extended release for the treatment of GNE myopathy. Data from the study are expected in 2017.. “Patients with GNE myopathy typically are diagnosed in their twenties and thirties, are wheelchair-bound within ten to..."/>
Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy
Flex Pharma, Inc., a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps, cramps and spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps, announced today that it will report its financial results for the second quarter ended June 30, 2016 on Wednesday, August 3, 2016 before the U.S. financial markets open. The Company will host a conference call and webcast at 8:45 a.m. ET..."/>
Flex Pharma to Report Second Quarter 2016 Results on August 3, 2016
Aeterna Zentaris Inc. will announce its second quarter 2016 financial and operating results after market close on Tuesday, August 9, 2016. The Company will host a conference call and webcast to discuss these results on Wednesday, August 10, 2016 at 8:30 a.m. Eastern Time. Participants may access the live webcast via the Company's website at www.aezsinc.com, or by telephone using the following number: 201-689-8029, Confirmation #13640170. A replay of the..."/>
Aeterna Zentaris to Announce Second Quarter 2016 Financial and Operating Results on August 9, 2016
Bioanalytical Systems, Inc., a recognized global leader in the development of instrumentation for electroanalytical measurements for over 40 years, is proud to partner with PalmSens BV to offer handheld electrochemical analyzers, expanding its line of innovative electrochemistry instrumentation. These cutting edge handheld electrochemical analyzers, now offered by BASi, are portable battery powered devices that are capable of Bluetooth..."/>
BASi Expands Electrochemical Offerings by Partnering with PalmSens BV
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it will host a conference call and webcast on Wednesday, August 3 rd, 2016 to discuss results for the period ended June 30, 2016 and to provide an update on current developments with respect to its clinical programs for Aramchol™. About Galmed..."/>
Galmed Pharmaceuticals Second Quarter 2016 Conference Call and Webcast Scheduled for Wednesday, August 3rd, 2016
WellCare Health Plans, Inc., announced today that it has signed agreements with BJC HealthCare and Washington University Physicians that give in-network coverage to Missouri Care's MO HealthNet Managed Care members. These agreements include access to medical centers, community hospitals, physician clinics, urgent care centers, ambulatory care centers, skilled nursing facilities and..."/>
Missouri Care Signs Agreements with BJC HealthCare and Washington University Physicians to Serve Missouri's Medicaid Population

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology778 Articles
Financials746 Articles
Consumer Discretionary663 Articles
Industrials491 Articles
Health Care482 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.